CELEBRATE MORE
WINNING HANDS

IMBRUVICA® gives patients with Waldenström’s macroglobulinemia an OPPORTUNITY TO LIVE LONGER WITHOUT PROGRESSION and continue to experience the things they love1

  • Estimated 54-month PFS was 68% with IMBRUVICA® + rituximab
    (95% CI: 54.8, 78.1) vs 25% with rituximab monotherapy
    (95% CI: 15.3, 36.6) (HR=0.25 [95% CI: 0.15, 0.42]; P<0.0001)1-3

 

LIVING LONGER WITHOUT PROGRESSION

Superior PFS with Up to 5 Years of Follow-up1-3

68% of patients estimated to be progression-free at 54 months with IMBRUVICA® + rituximab (95% CI: 54.8, 78.1) vs 25% with rituximab monotherapy (95% CI: 15.3, 36.6) (HR=0.25 [95% CI: 0.15, 0.42]; P<0.0001)

CONFIDENCE WITH EXPERIENCE

5+ Years Established Safety and Tolerability Profile1

The safety data from long-term follow-up over 5 years in both treatment-naïve and relapsed/refractory WM patients (N=106)

WM

INDICATION1

IMBRUVICA® (ibrutinib) is a once-daily oral therapy indicated for the treatment of adult patients with Waldenström's Macroglobulinemia (WM).

CI=confidence interval, HR=hazard ratio, PFS=progression-free survival, WM=Waldenström's Macroglobulinemia.

References: 1IMBRUVICA® (ibrutinib) Prescribing Information. 2Data on file. 3Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022;40(1):52-62. doi:10.1200/JCO.21.00838